Date Filed | Type | Description |
10/12/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
10/12/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
10/11/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
10/10/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
10/10/2023 |
8-K
| Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other E...
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"AGREEMENT AND PLAN OF MERGER among: MIRATI THERAPEUTICS, INC., a Delaware corporation; BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation; and VINEYARD MERGER SUB INC.,",
"AMENDMENT TO BYLAWS OF MIRATI THERAPEUTICS, INC. ARTICLE XV MISCELLANEOUS",
"ARTICLE XV MISCELLANEOUS",
"Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio with Acquisition of Mirati Therapeutics",
"Voting and Support Agreement, by and among Bristol-Myers Squibb Company, Boxer Capital, LLC, and MVA Investors, LLC" |
|
10/10/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
10/10/2023 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material: |
10/05/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
10/02/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
08/23/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
08/16/2023 |
SC 13D/A
| Boxer Capital, LLC reports a 15.9% stake in Mirati Therapeutics, Inc. |
08/15/2023 |
4
| Boxer Capital, LLC (See remarks) has filed a Form 4 on Mirati Therapeutics, Inc.
Txns:
| Bought 57,533 shares
@ $27.8, valued at
$1.6M
Bought 1,201,440 shares
@ $27.8, valued at
$33.4M
|
|
08/15/2023 |
4
| Boxer Capital, LLC (See remarks) has filed a Form 4 on Mirati Therapeutics, Inc.
Txns:
| Bought 57,533 shares
@ $27.8, valued at
$1.6M
Bought 1,201,440 shares
@ $27.8, valued at
$33.4M
|
|
08/14/2023 |
4
| Hasnain Faheem (Director) has filed a Form 4 on Mirati Therapeutics, Inc.
Txns:
| Bought 10,791 shares
@ $27.8, valued at
$300k
|
|
08/10/2023 |
4
| Stelzer Laurie (CFO) has filed a Form 4 on Mirati Therapeutics, Inc.
Txns:
| Granted 22,297 shares
@ $37, valued at
$825k
|
|
08/10/2023 |
4
| BAUM CHARLES M (Interim CEO) has filed a Form 4 on Mirati Therapeutics, Inc.
Txns:
| Granted 54,054 shares
@ $37, valued at
$2M
|
|
08/10/2023 |
4
| Hickey Benjamin (EVP, Chief Commercial Officer) has filed a Form 4 on Mirati Therapeutics, Inc.
Txns:
| Granted 22,297 shares
@ $37, valued at
$825k
|
|
08/10/2023 |
4
| Moriarty John B (Chief Legal Officer) has filed a Form 4 on Mirati Therapeutics, Inc.
Txns:
| Granted 22,297 shares
@ $37, valued at
$825k
|
|
08/10/2023 |
4
| Christensen Jamie (EVP & Chief Scientific Officer) has filed a Form 4 on Mirati Therapeutics, Inc.
Txns:
| Granted 22,297 shares
@ $37, valued at
$825k
|
|
08/10/2023 |
4
| Sandler Alan B. (Chief Medical Officer) has filed a Form 4 on Mirati Therapeutics, Inc.
Txns:
| Granted 22,297 shares
@ $37, valued at
$825k
|
|
08/09/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
08/09/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
08/08/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
08/08/2023 |
8-K
| Quarterly results, Appointed a new director |
07/21/2023 |
8-K
| Quarterly results |
06/02/2023 |
4
| Stelzer Laurie (CFO) has filed a Form 4 on Mirati Therapeutics, Inc.
Txns:
| Sold 4,647 shares
@ $37.06, valued at
$172.2k
|
|
05/24/2023 |
4
| Christensen Jamie (EVP & Chief Scientific Officer) has filed a Form 4 on Mirati Therapeutics, Inc.
Txns:
| Sold 619 shares
@ $45.2905, valued at
$28k
|
|
05/24/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
05/12/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
05/09/2023 |
8-K
| Quarterly results |
04/06/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
04/05/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
|